Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challenges, including post-prandial hyperglycemia and exercise-related dysglycemia.
Get full access to this article
View all access options for this article.
References
1.
FosterNC, BeckRW, MillerKM, et al.: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21:66–72.
2.
GargSK, WeinzimerSA, TamborlaneWV, et al.: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
3.
ForlenzaGP, Pinhas-HamielO, LiljenquistDR, et al.: Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther, 2019; 21:11–19.
4.
DuffusSH, Al Ta'aniZ, SlaughterJC, et al.: Increased proportion of time in hybrid closed-loop “auto mode” is associated with improved glycemic control for adolescent and young adult type 1 diabetes patients using the MiniMed 670G insulin pump. Diabetes Obes Metab, 2019. [Epub ahead of print]; DOI: 10.1111/dom.13912.
5.
LeeMH, VogrinS, PaldusB, et al.: Glucose control in adults with type 1 diabetes using a medtronic prototype enhanced-hybrid closed-loop system: a feasibility study. Diabetes Technol Ther, 2019; 21:499–506.
6.
BrownS, RaghinaruD, EmoryE, KovatchevB: First look at Control-IQ: a new-generation automated insulin delivery system. Diabetes Care, 2018; 41:2634–2636.
7.
BrownSA, KovatchevBP, RaghinaruD, et al.: Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381:1707–1717.
8.
Four pivotalNIH-funded artificial pancreas research efforts begin, 2017. nih.gov/news-events/news-releases-four-pivotal-nih-funded-artificial-pancreas-research-efforts-begin (accessed January29, 2020).
9.
ThabitH, TauschmannM, AllenJM, et al.: Home use of an artificial beta cell in type 1 diabetes. N Engl J Med, 2015; 373:2129–2140.
10.
TauschmannM, ThabitH, BallyL, et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet, 2018; 392:1321–1329.
11.
PhillipM, BattelinoT, AtlasE, et al.: Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med, 2013; 368:824–833.
12.
BiesterT, NirJ, RemusK, et al.: DREAM5: an open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home. Diabetes Obes Metab, 2018; 21:822–828.
13.
ForlenzaGP, BuckinghamBA, ChristiansenMP, et al.: Performance of omnipod personalized model predictive control algorithm with moderate intensity exercise in adults with type 1 diabetes. Diabetes Technol Ther, 2019; 21:265–272.
14.
SherrJL, BuckinghamBA, ForlenzaGP, et al.: Safety and performance of the Omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions. Diabetes Technol Ther, 2020; 22:174–184.
15.
BenhamouPY, FrancS, ReznikY, et al.: Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digital Health, 2019; 1:e17–e25.
What the FDA's new ACEPump indication means for people with diabetes, Tidepool, and TidepoolLoop. LookH: 2019. Tidepool.org/blog/what-ace-pump-means-for-tidepool-loop (accessed January29, 2020).
19.
HeiseT, ZijlstraE, NosekL, et al.: Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial. Diabetes Obes Metab, 2017; 19:208–215.
20.
DovcK, PionaC, Yesiltepe MutluG, et al.: Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial. Diabetes Care, 2020; 43:29–36.
21.
HeiseT, MeiffrenG, AlluisB, et al.: BioChaperone lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomized euglycemic clamp study. Diabetes Obes Metab, 2019; 21:1066–1070.
22.
McCrimmonRJ, SherwinRS: Hypoglycemia in type 1 diabetes. Diabetes, 2010; 59:2333–2339.
23.
SherrJL, PatelNS, MichaudCI, et al.: Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care, 2016; 39:1127–1134.
24.
WeinzimerSA, SherrJL, CengizE, et al.: Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care, 2012; 35:1994–1999.
25.
IlkowitzJT, KatikaneniR, CantwellM, et al.: Adjuvant liraglutide and insulin versus insulin monotherapy in the closed-loop system in type 1 diabetes: a randomized open-labeled crossover design trial. J Diabetes Sci Technol, 2016; 10:1108–1114.
26.
RiddleMC, NahraR: Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: a randomized, two-way crossover study. Diabetes Care, 2018; 41:2346–2352.
27.
HaidarA, TsoukasMA, Bernier-TwardyS, YaleJF, RutkowskiJ, BossyA, PytkaE, El FathiA, StraussN, LegaultL. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial. Diabetes Care. 2020 Mar, 1; 43(3):597–606.
28.
AgrawalP, WelshJB, KannardB, et al.: Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol, 2011; 5:1137–1141.
29.
ForlenzaGP, LiZ, BuckinghamBA, et al.: Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care, 2018; 41:2155–2161.
30.
BekiariE, KitsiosK, ThabitH, et al.: Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ, 2018; 361:k1310.
31.
CastleJR, EngleJM, El YoussefJ, et al.: Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care, 2010; 33:1282–1287.
32.
RussellSJ, El-KhatibFH, SinhaM, et al.: Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med, 2014; 371:313–325.
33.
van BonAC, LuijfYM, KoebruggeR, et al.: Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther, 2014; 16:131–136.
34.
HaidarA, LegaultL, MessierV, et al.: Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol, 2015; 3:17–26.
35.
El-KhatibFH, BalliroC, HillardMA, et al.: Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet, 2017; 389:369–380.
CastleJR, ElanderM: Long-term safety and tolerability of dasiglucagon, a stable-in-solution glucagon analogue. Diabetes Technol Ther, 2019; 21:94–96.
38.
BretonMD, ChernavvskyDR, ForlenzaGP, et al.: Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study. Diabetes Care, 2017; 40:1644–1650.
39.
CastleJR, El YoussefJ, WilsonLM, et al.: Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care, 2018; 41:1471–1477.
40.
JacobsPG, ResalatN, El YoussefJ, et al.: Incorporating an exercise detection, grading, and hormone dosing algorithm into the artificial pancreas using accelerometry and heart rate. J Diabetes Sci Technol, 2015; 9:1175–1184.
41.
ReddyR, WittenbergA, CastleJR, et al.: Effect of aerobic and resistance exercise on glycemic control in adults with type 1 diabetes. Can J Diabetes, 2019; 43:406–414.
42.
YardleyJE, KennyGP, PerkinsBA, et al.: Resistance versus aerobic exercise: acute effects on glycemia in type 1 diabetes. Diabetes Care, 2013; 36:537–542.
43.
RiddellMC, GallenIW, SmartCE, et al.: Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol, 2017; 5:377–390.
44.
WeinzimerSA, SteilGM, SwanKL, et al.: Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care, 2008; 31:934–939.
45.
LeahyJJL, AleppoG, FonsecaVA, et al.: Optimizing postprandial glucose management in adults with insulin-requiring diabetes: report and recommendations. J Endocr Soc, 2019; 3:1942–1957.
46.
ForlenzaGP, CameronFM, LyTT, et al.: Fully closed-loop multiple model probabilistic predictive controller artificial pancreas performance in adolescents and adults in a supervised hotel setting. Diabetes Technol Ther, 2018; 20:335–343.
47.
RamkissoonCM, HerreroP, BondiaJ, VehiJ: Unannounced meals in the artificial pancreas: detection using continuous glucose monitoring. Sensors, 2018; 18:884.
48.
BancksMP, CasanovaR, GreggEW, BertoniAG: Epidemiology of diabetes phenotypes and prevalent cardiovascular risk factors and diabetes complications in the National Health and Nutrition Examination Survey 2003–2014. Diabetes Res Clin Pract, 2019; 158:107915.
49.
BallyL, GublerP, ThabitH, et al.: Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int, 2019; 96:593–596.
50.
StewartZA, WilinskaME, HartnellS, et al.: Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med, 2016; 375:644–654.
51.
AbitbolA, Rabasa-LhoretR, MessierV, et al.: Overnight glucose control with dual- and single-hormone artificial pancreas in type 1 diabetes with hypoglycemia unawareness: a randomized controlled trial. Diabetes Technol Ther, 2018; 20:189–196.
52.
Nevo-ShenkerM, PhillipM, NimriR, ShalitinS: Type 1 diabetes mellitus management in young children: implementation of current technologies. Pediatr Res, 2019. DOI: 10.1038/s41390-019-0665-4.
53.
BallyL, ThabitH, HartnellS, et al.: Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med, 2018; 379:547–556.
54.
BoughtonCK, BallyL, MartignoniF, et al.: Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol, 2019; 7:368–377.
55.
FarringtonC: Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review. Diabet Med, 2018; 35:436–449.
